Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

Last updated: November 20, 2024
Sponsor: Jerry Cochran
Overall Status: Completed

Phase

N/A

Condition

Opioid Use Disorder

Treatment

Implementation of the BINDeR-Tx service model

Clinical Study ID

NCT06087991
158724
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.

Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.

Eligibility Criteria

Inclusion

Inclusion Criteria:

For qualitative interviews with providers, administrators, stakeholders:

  • Must be affiliated with Castleview Hospital as a provider, administrator orstakeholder.

For the quantitative surveys:

  • Must be a Castleview Hospital patient who receives the BINDeR-Tx model.

Exclusion

Exclusion Criteria:

For qualitative interviews with providers, administrators, stakeholders:

  • Not familiar with the BINDeR-Tx model

  • No interaction with the BINDeR-Tx model

For the quantitative surveys:

  • Unable to speak and read English

  • Subject is unable to provide contact information

Study Design

Total Participants: 31
Treatment Group(s): 1
Primary Treatment: Implementation of the BINDeR-Tx service model
Phase:
Study Start date:
April 01, 2023
Estimated Completion Date:
October 01, 2024

Study Description

Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.

The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.

This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.

Connect with a study center

  • University of Utah

    Salt Lake City, Utah 84108
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.